MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1177/18632521241235028

Медицинская библиотека · Journal of children's orthopaedics · 2024

Nusinersen therapy changed the natural course of spinal muscular atrophy type 1: What about spine and hip?

Yasar Niyazi Erdem, Ozdemir Guzelali, Uzun Ata Elif, Ayvali Mustafa Okan, Ata Naim, Ulgu Mahir, Dumlupınar Ebru, Birinci Suayip, Bingol Izzet, Bekmez Senol

СтатьяПеревод в очереди

Аннотация

PURPOSE: Spinal muscular atrophy type 1 has a devastating natural course and presents a severe course marked by scoliosis and hip subluxation in nonambulatory patients. Nusinersen, Food and Drug Administration-approved spinal muscular atrophy therapy, extends survival and enhances motor function. However, its influence on spinal and hip deformities remains unclear.

METHODS

In a retrospective study, 29 spinal muscular atrophy type 1 patients born between 2017 and 2021, confirmed by genetic testing, treated with intrathecal nusinersen, and had registered to the national electronic health database were included. Demographics, age at the first nusinersen dose, total administrations, and Children's of Philadelphia Infant Test of Neuromuscular Disorders scores were collected. Radiological assessments included parasol rib deformity, scoliosis, pelvic obliquity, and hip subluxation.

RESULTS

Mean age was 3.7 ± 1.1 (range, 2-6), and average number of intrathecal nusinersen administration was 8.9 ± 2.9 (range, 4-19). There was a significant correlation between Children's of Philadelphia Infant Test of Neuromuscular Disorders score and the number of nusinersen administration (r = 0.539, p = 0.05). The correlation between Children's of Philadelphia Infant Test of Neuromuscular Disorders score and patient age (r = 0.361) or the time of first nusinersen dose (r = 0.39) was not significant (p = 0.076 and p = 0.054, respectively). While 93.1% had scoliosis, 69% had pelvic obliquity, and 60.7% had hip subluxation, these conditions showed no significant association with patient age, total nusinersen administrations, age at the first dose, or Children's of Philadelphia Infant Test of Neuromuscular Disorders scores.

CONCLUSION

Disease-modifying therapy provides significant improvements in overall survival and motor function in spinal muscular atrophy type 1. However, progressive spine deformity and hip subluxation still remain significant problems in the majority of cases which would potentially need to be addressed.

Для цитирования: Yasar Niyazi Erdem, Ozdemir Guzelali, Uzun Ata Elif, Ayvali Mustafa Okan, Ata Naim, Ulgu Mahir, Dumlupınar Ebru, Birinci Suayip, Bingol Izzet, Bekmez Senol. Nusinersen therapy changed the natural course of spinal muscular atrophy type 1: What about spine and hip?. Journal of children's orthopaedics. 2024. DOI: 10.1177/18632521241235028.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.